Monte Rosa Announces Positive GFORCE-1 Phase 1 Atherosclerosis Study Results for MRT-8102
Monte Rosa Therapeutics reported degrader MRT-8102 normalized key ASCVD drivers in obese subjects with high CVD risk, revealing a favorable safety profile and opening pathways for phase 2 trials in heart disease and chronic inflammation.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed